Covid-19: Handling of Marketing Authorisations
Recommendation
Tuesday, 23 September 2025 13.00 - 17.00 h
Register now for ECA's GMP Newsletter
The processes and procedures relating to marketing authorisations are still strongly influenced by the corona pandemic. On the website of the HMA (Heads of Medicines Agencies) this has been reiterated and the available templates and information to facilitate and manage marketing authorisations and registration procedures have been consolidated and listed.
In addition to the continuously updated catalogue"QUESTIONS AND ANSWERS ON REGULATORY EXPECTATIONS FOR MEDICINAL PRODUCTS FOR HUMAN USE DURING THE COVID-19 PANDEMIC", the "Template for submission of an application for a Covid-19 exeptional change management process (ECMP)" and the "Template for Step 3 Notification of implementation" are available here.
The overview of the information provided and application templates can be found on the website of the HMA (Heads of Medicines Agencies) in the section CMDh.
Related GMP News
06.08.2025WHO: TRS 1060 regulatory Guidelines published
30.07.2025Swissmedic/EMA: M4Q(R2) Guideline published for Comment
23.07.2025FDA: Complete Response Letters published
02.07.2025ICH M4Q Guideline Updated
04.06.2025EDQM: Update of Guideline "How to read a CEP"
16.04.2025EMA: Revised IRIS Documents